Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept

Joint Bone Spine

Volumn 83, Issue 6, 2016, Pages 675-679

  Rákóczi, Éva ^a   Perge, Bianka ^b   Végh, Edit ^b   Csomor, Péter ^b   Pusztai, Anita ^b   Szamosi, Szilvia ^b   Bodnár, Nóra ^b   Szántó, Sándor ^b   Szücs, Gabriella ^b   Szekanecz, Zoltán ^b  

^a Kenezy Korhaz Rendelointezet   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Conjugated pneumococcal vaccine; Etanercept; PCV13; Protective antibody level; Rheumatoid arthritis

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; ETANERCEPT; IMMUNOGLOBULIN G; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; ANTIRHEUMATIC AGENT;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELISA KIT; EVALUATION STUDY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOGENICITY; INFECTION; MALE; MIDDLE AGED; MONOTHERAPY; PAIN; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; VACCINATION; AGED; ANTIBODY PRODUCTION; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; PATHOPHYSIOLOGY; PATIENT SAFETY; PHYSIOLOGIC MONITORING; PROCEDURES; STREPTOCOCCUS PNEUMONIA; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PATIENT SAFETY; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84961186965     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.10.017     Document Type: Article

References (26)

1. [1] Hernandez-Cruz, B., Cardiel, M.H., Villa, A.R., et al. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 25 (1998), 1900–1907.
2. [2] Franklin, J., Lunt, M., Bunn, D., et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 66 (2007), 308–312.
3. [3] Henrichsen, J., Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 33 (1995), 2759–2762.
4. [4] Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec 82 (2007), 93–104.
5. [5] Ochoa, T.J., Rupa, R., Guerra, H., et al. Penicillin resistance and serotypes/serogroups of Streptococcus pneumoniae in nasopharyngeal carrier children younger than 2 years in Lima, Peru. Diagn Microbiol Infect Dis 52 (2005), 59–64.
6. [6] Center for Disease Control and Prevention (CDC), Advisory Comittee on Imunization Practrices, Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 59 (2010), 1102–1106.
7. [7] Aliberti, S., Mantero, M., Mirsaeidi, M., et al. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect 20 (2014), 52–58.
8. [8] Kapetanovic, M.C., Roseman, C., Jonsson, G., et al. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin Rheumatol 30 (2011), 1555–1561.
9. [9] van Assen, S., Agmon-Levin, N., Elkayam, O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70 (2011), 414–422.
10. [10] Gelinck, L.B., Teng, Y.K., Rimmelzwaan, G.F., et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66 (2007), 1402–1403.
11. [11] Gelinck, L.B., van der Bijl, A.E., Beyer, W.E., et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67 (2008), 713–716.
12. [12] Elkayam, O., Caspi, D., Reitblatt, T., et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33 (2004), 283–288.
13. [13] Nagel, J., Geborek, P., Saxne, T., et al. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Res Ther, 17, 2015, 124.
14. [14] Nagel, J., Geborek, P., Saxne, T., et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol 44 (2015), 271–279.
15. [15] Elkayam, O., Bashkin, A., Mandelboim, M., et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 39 (2009), 442–447.
16. [16] Kapetanovic, M.C., Roseman, C., Jonsson, G., et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 63 (2011), 3723–3732.
17. [17] Crnkic Kapetanovic, M., Saxne, T., Jonsson, G., et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther, 15, 2013, R171.
18. [18] Crnkic Kapetanovic, M., Saxne, T., Truedsson, L., et al. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther, 15, 2013, R1.
19. [19] Mori, S., Ueki, Y., Akeda, Y., et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 72 (2013), 1362–1366.
20. [20] Falup-Pecurariu, O., Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines. Biomed J 35 (2012), 450–456.
21. [21] Scott, L.J., Sanford, M., Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults. Drugs Aging 29 (2012), 847–855.
22. [22] Center for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 61 (2012), 816–819.
23. [23] Bonten, M.J., Huijts, S.M., Bolkenbaas, M., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372 (2015), 1114–1125.
24. [24] Orange, J.S., Ballow, M., Stiehm, E.R., et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 130 (2012), S1–S24.
25. [25] Salinas, G.F., De Rycke, L., Barendregt, B., et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 72 (2013), 1037–1043.
26. [26] Kapetanovic, M.C., Saxne, T., Sjoholm, A., et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45 (2006), 106–111.